Rationales for treating IgA nephropathies. - Wikidata - awgldk - TriplyDB

Rationales for treating IgA nephropathies.

Rationales for treating IgA nephropathies.

http://www.wikidata.org/entity/Q33863555

about

Effect of 12-month therapy with omega-3 polyunsaturated acids on glomerular filtration response to dopamine in IgA nephropathy.

P2860

Q45038963-7153B58F-2B0D-4246-A648-187CD5AAC5ED

P2860

Rationales for treating IgA nephropathies.

http://www.wikidata.org/entity/Q33863555

description

2000 nî lūn-bûn

@nan

2000 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Rationales for treating IgA nephropathies.

@ast

Rationales for treating IgA nephropathies.

@en

type

label

Rationales for treating IgA nephropathies.

@ast

Rationales for treating IgA nephropathies.

@en

prefLabel

Rationales for treating IgA nephropathies.

@ast

Rationales for treating IgA nephropathies.

@en

P1433

Q33863555-EA722F24-854F-4350-B9D7-7E3688D01CD7

P1476

Q33863555-21FE1D0B-D0E4-4161-873F-59197E41546E

P2093

Q33863555-9264BB72-1CA0-45BA-8BB8-BA0E35A921F3

P2860

Q33863555-032400E4-978A-41B6-93EA-3385293E9973

Q33863555-085AC65A-8D4D-44FA-8479-8D5BDD0D3206

Q33863555-08C0D6D4-C3E1-4E91-B082-CEB27849481A

Q33863555-14511A97-049E-4E40-8C80-D135439AF1B4

Q33863555-19A0D353-8000-41F5-8BBC-1B1E99A5B9FF

Q33863555-1B3E7D54-84C0-4E09-9505-D303A6D17F16

Q33863555-1D8BAED8-5E90-4CE6-88C9-55C30AEA727F

Q33863555-28597F3E-6982-48D7-91B8-C624507C7D2F

Q33863555-2DF5B7C0-DF5F-46BB-B4B7-81EBA3BEF4F8

Q33863555-31A0F8A6-38F8-41D7-A43F-E4BE3469367B

P304

Q33863555-567A1AA0-BE5A-4AD6-8154-56E7892FD56B

P31

Q33863555-D956D742-2841-4315-88D1-AEEE677F1D40

P356

Q33863555-6E948608-86B0-4711-BCAC-3A932A12B759

P433

Q33863555-3D4CBA00-122C-49A6-B9ED-A9783B477058

P478

Q33863555-4D383148-3B61-47CE-BD69-211845C4F3BD

P577

Q33863555-5483DD9E-E2CB-4762-BDF7-CE15E04FE175

P698

Q33863555-5FB166BA-4AE0-464C-AC85-B4463EED11BE

P356

P1433

P1476

Rationales for treating IgA nephropathies.

@en

P2093

Wardle EN

http://www.w3.org/2001/XMLSchema#string

P2860

Increased glomerular thromboxane synthesis as a possible cause of proteinuria in experimental nephrosis

Acute haemodynamic and proteinuric effects of prednisolone in patients with a nephrotic syndrome

Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion.

Asthma and leukotrienes: antileukotrienes as novel anti-asthmatic drugs.

Regulation of transforming growth factor-beta 1 gene expression by glucocorticoids in normal human T lymphocytes

A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group.

Antileukotrienes in the treatment of asthma.

Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes.

Neutrophil oxygen radical generation. Synergistic responses to tumor necrosis factor and mono/polyunsaturated fatty acids.

Aberrant glycosylation of IgA from patients with IgA nephropathy.

P304

1-16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1081/JDI-100100846

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2000-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10718276

http://www.w3.org/2001/XMLSchema#string